Exelixis Inc. (EXEL) fundamentals score
Exelixis, Inc. (Exelixis, we, its or it) is an oncology company innovating next-generation medicines and regimens at the forefront of cancer care.
Biological Products, (No Diagnostic Substances) · Healthcare · Listed on NASDAQ
Overall: 8.8 out of 10, Strong long-term fundamentals
- Growth: 6.7/10
- Profitability: 9.6/10
- Financial health: 9.5/10
- Earnings quality: 9.2/10
- Valuation: 9.4/10
Scores are calculated from Exelixis Inc.’s SEC filings, using the 12 months through 2026-07. Compare it with past big winners, check its flags, and see today’s price against its fundamentals in the full scorecard.
Other Healthcare stocks
- Nurix Therapeutics, Inc. (NRIX): 9.0/10
- Caredx, Inc. (CDNA): 8.9/10
- Dexcom, Inc. (DXCM): 8.8/10
- Neurocrine Biosciences Inc. (NBIX): 8.7/10
- Progyny, Inc. (PGNY): 8.6/10
- Healthcare Services Group, Inc. (HCSG): 8.5/10
- Insulet Corporation (PODD): 8.5/10
- Globus Medical, Inc. (GMED): 8.4/10